The following publication generated a considerable amount of interest several months ago in HU’s Advanced Prostate Group.
“Association between post-diagnostic use of cholera vaccine and risk of death in prostate cancer patients”, Jianguang Ji, Jan Sundquist, & Kristina Sundquist, Nat Commun. 2018; 9: 2367. 2018 Jun 18. doi: 10.1038/s41467-018-04814-4
ncbi.nlm.nih.gov/pmc/articl...
The paper describes the effect of the vaccine on mortality rates of men who took the Dukoral cholera vaccine before and after diagnosis for PCa. The authors found that there was a benefit for both groups. Importantly, the authors indicated that the HR for post diagnosis users was the lowest at 15 months and increased gradually thereafter. The paper discusses only the benefits of a single vaccination event – there is no mention of the effect of multiple vaccination events. I was considering contacting the authors to determine if they have the data for multiple vaccination events.
For first time users, the vaccine is taken in two parts, two weeks apart. According to the Dukoral literature the immunity imparted by the vaccine against enterotoxigenic E. Coli lasts about 3 months and about 2 years against Cholera. The immunity imparted by the vaccine declines with time and a booster vaccination with a single vial is necessary after 2 – 5 years.
It would appear that after the initial vaccination with two vials that the vaccine should be taken on a regular basis for the purposes of slowing the progression of PCa. Based on Figure 1 in the paper, I would say a booster vaccination should be taken every 12-15 months.
I hope this generates some discussion. Cheers, Phil